CU20120153A7 - Antígenos vacunales quiméricos contra el virus de la hepatitis c - Google Patents

Antígenos vacunales quiméricos contra el virus de la hepatitis c

Info

Publication number
CU20120153A7
CU20120153A7 CUP2012000153A CU20120153A CU20120153A7 CU 20120153 A7 CU20120153 A7 CU 20120153A7 CU P2012000153 A CUP2012000153 A CU P2012000153A CU 20120153 A CU20120153 A CU 20120153A CU 20120153 A7 CU20120153 A7 CU 20120153A7
Authority
CU
Cuba
Prior art keywords
virus
antigens
chimeric
chemical
against hepatitis
Prior art date
Application number
CUP2012000153A
Other languages
English (en)
Other versions
CU24112B1 (es
Inventor
Carrera Santiago Dueñas
Noriega Daylen Aguilar
Cañizares Yalena Amador
Ponce De León Liz Álvarez-Lajonchere
Donato Gillian Martínez
Blanco Sonia González
Original Assignee
Ct De Ingeniería Genética Y Biotecnología
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct De Ingeniería Genética Y Biotecnología filed Critical Ct De Ingeniería Genética Y Biotecnología
Priority to CU20120153A priority Critical patent/CU24112B1/es
Priority to PCT/CU2013/000006 priority patent/WO2014067498A1/es
Priority to ES13801461.8T priority patent/ES2644801T3/es
Priority to CA2901346A priority patent/CA2901346C/en
Priority to EP13801461.8A priority patent/EP2915544B1/en
Priority to CN201380064380.9A priority patent/CN104837498B/zh
Priority to US14/440,443 priority patent/US9676825B2/en
Priority to RU2015121429A priority patent/RU2639504C2/ru
Priority to IN3925DEN2015 priority patent/IN2015DN03925A/en
Priority to MX2015005651A priority patent/MX358507B/es
Priority to AU2013339846A priority patent/AU2013339846B2/en
Priority to JP2015540044A priority patent/JP6259831B2/ja
Priority to KR1020157012656A priority patent/KR102093495B1/ko
Priority to ARP130104019A priority patent/AR093341A1/es
Publication of CU20120153A7 publication Critical patent/CU20120153A7/es
Priority to ZA2015/03036A priority patent/ZA201503036B/en
Publication of CU24112B1 publication Critical patent/CU24112B1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/29Hepatitis virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24211Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24211Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24271Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención describe antígenos vacunales quiméricos contra el virus de la hepatitis C (VHC) que comprenden regiones seleccionadas de diferentes antígenos de dicho virus, las que se ubican en un orden determinado dentro del polipéptido. Dichos antígenos quiméricos, además, pueden incluir epitopos específicos para linfocitos T auxiliadores, diseñados de forma artificial. Los antígenos quiméricos, así como las composiciones vacunales resultantes, son aplicables a la esfera de la medicina y la industria farmacéutica, y tienen un uso profiláctico y/o terapéutico contra el VHC. Las composiciones vacunales de la invención generan una respuesta inmune potente y de amplio espectro contra diferentes antígenos de dicho virus, con un mínimo de componentes.
CU20120153A 2012-11-05 2012-11-05 Antígenos vacunales quiméricos contra el virus de la hepatitis c CU24112B1 (es)

Priority Applications (15)

Application Number Priority Date Filing Date Title
CU20120153A CU24112B1 (es) 2012-11-05 2012-11-05 Antígenos vacunales quiméricos contra el virus de la hepatitis c
RU2015121429A RU2639504C2 (ru) 2012-11-05 2013-10-28 Химерные антигены для вакцины против вируса гепатита с
IN3925DEN2015 IN2015DN03925A (es) 2012-11-05 2013-10-28
CA2901346A CA2901346C (en) 2012-11-05 2013-10-28 Chimeric vaccine antigens against hepatitis c virus
EP13801461.8A EP2915544B1 (en) 2012-11-05 2013-10-28 Chimeric vaccine antigens against hepatitis c virus
CN201380064380.9A CN104837498B (zh) 2012-11-05 2013-10-28 针对丙型肝炎病毒的嵌合疫苗抗原
US14/440,443 US9676825B2 (en) 2012-11-05 2013-10-28 Chimeric vaccine antigens against hepatitis C virus
PCT/CU2013/000006 WO2014067498A1 (es) 2012-11-05 2013-10-28 Antígenos vacunales quiméricos contra el virus de la hepatitis c
ES13801461.8T ES2644801T3 (es) 2012-11-05 2013-10-28 Antígenos de vacuna quimérica contra el virus de la hepatitis c
MX2015005651A MX358507B (es) 2012-11-05 2013-10-28 Antigenos vacunales quimericos contra el virus de la hepatitis c.
AU2013339846A AU2013339846B2 (en) 2012-11-05 2013-10-28 Chimeric vaccine antigens against hepatitis C virus
JP2015540044A JP6259831B2 (ja) 2012-11-05 2013-10-28 C型肝炎ウイルスに対するキメラワクチン抗原
KR1020157012656A KR102093495B1 (ko) 2012-11-05 2013-10-28 C형 간염 바이러스에 대한 키메라 백신 항원
ARP130104019A AR093341A1 (es) 2012-11-05 2013-11-04 Antigenos vacunales quimericos contra el virus de la hepatitis c
ZA2015/03036A ZA201503036B (en) 2012-11-05 2015-05-04 Chimeric vaccine antigens against hepatitis c virus

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20120153A CU24112B1 (es) 2012-11-05 2012-11-05 Antígenos vacunales quiméricos contra el virus de la hepatitis c

Publications (2)

Publication Number Publication Date
CU20120153A7 true CU20120153A7 (es) 2014-06-27
CU24112B1 CU24112B1 (es) 2015-08-27

Family

ID=49724426

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20120153A CU24112B1 (es) 2012-11-05 2012-11-05 Antígenos vacunales quiméricos contra el virus de la hepatitis c

Country Status (15)

Country Link
US (1) US9676825B2 (es)
EP (1) EP2915544B1 (es)
JP (1) JP6259831B2 (es)
KR (1) KR102093495B1 (es)
CN (1) CN104837498B (es)
AR (1) AR093341A1 (es)
AU (1) AU2013339846B2 (es)
CA (1) CA2901346C (es)
CU (1) CU24112B1 (es)
ES (1) ES2644801T3 (es)
IN (1) IN2015DN03925A (es)
MX (1) MX358507B (es)
RU (1) RU2639504C2 (es)
WO (1) WO2014067498A1 (es)
ZA (1) ZA201503036B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3319997A4 (en) * 2015-07-07 2019-01-23 The Governors of the University of Alberta IMMUNOGENIC COMPOSITIONS BASED ON HEPATITIS C VIRUS AND METHODS OF USE
CN109963587A (zh) * 2016-09-21 2019-07-02 艾伯塔大学理事会 丙型肝炎病毒免疫原性组合物及其使用方法
AU2018258575A1 (en) 2017-04-27 2019-11-07 The Johns Hopkins University Hepatitis C virus gene sequences and methods of use therefor
WO2019173925A1 (en) * 2018-03-16 2019-09-19 The Governors Of The University Of Alberta Hepatitis c virus peptide compositions and methods of use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001037869A1 (en) 1999-11-19 2001-05-31 Csl Limited Vaccine compositions
US6544780B1 (en) * 2000-06-02 2003-04-08 Genphar, Inc. Adenovirus vector with multiple expression cassettes
CU23496A1 (es) * 2004-09-03 2010-02-23 Ct Ingenieria Genetica Biotech Composición vacunal contra el virus de la hepatitis c
CA2636032C (en) * 2006-01-04 2016-04-12 Novartis Vaccines And Diagnostics, Inc. Activation of hcv-specific t cells
US7256008B2 (en) 2006-01-06 2007-08-14 Abbott Laboratories Determination of concentration of FK778 by competitive immunoassay
WO2009056535A2 (en) * 2007-10-29 2009-05-07 Genimmune N.V. Methods and kits for inducing a ctl response using a prime boost regimen
CN102016026B (zh) * 2008-04-25 2014-07-02 东丽株式会社 含有来自丙型肝炎病毒的嵌合基因的核酸
EP2331125A4 (en) * 2008-09-19 2013-03-27 Globeimmune Inc IMMUNOTHERAPY FOR CHRONIC HEPATITIS C-VIRUS INFECTIONS
US20110311550A1 (en) * 2008-10-24 2011-12-22 The Scripps Research Institute Agents for hcv treatment

Also Published As

Publication number Publication date
CN104837498A (zh) 2015-08-12
ZA201503036B (en) 2016-01-27
CA2901346A1 (en) 2014-05-08
RU2639504C2 (ru) 2017-12-21
CN104837498B (zh) 2018-05-18
KR20150079694A (ko) 2015-07-08
US20150307558A1 (en) 2015-10-29
WO2014067498A1 (es) 2014-05-08
AU2013339846A1 (en) 2015-05-14
MX358507B (es) 2018-08-22
EP2915544B1 (en) 2017-08-09
CA2901346C (en) 2019-04-23
JP2015536936A (ja) 2015-12-24
CU24112B1 (es) 2015-08-27
RU2015121429A (ru) 2016-12-27
AU2013339846B2 (en) 2017-08-17
ES2644801T3 (es) 2017-11-30
US9676825B2 (en) 2017-06-13
KR102093495B1 (ko) 2020-03-26
EP2915544A1 (en) 2015-09-09
JP6259831B2 (ja) 2018-01-10
IN2015DN03925A (es) 2015-10-02
AR093341A1 (es) 2015-06-03
MX2015005651A (es) 2015-08-20

Similar Documents

Publication Publication Date Title
CL2017001610A1 (es) Anticuerpos humanos para hemagglutinina de influenza
NI201800052A (es) Anticuerpos que neutraliza el virus respiratorio sincitial humano
CL2018000232A1 (es) Mezcla de péptidos (divisional solicitud 201601405)
MX2019004913A (es) Vacunas de nanoparticulas lipidicas que comprenden acido ribonucleico mensajero (arnm).
DOP2018000146A (es) Anticuerpos neutralizadores del virus de inmunodeficiencia humana
IL259942A (en) Antigens, vectors, preparations, methods and their use for the human immunodeficiency virus
CR20180174A (es) Nuevos péptidos, combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer
EA201591164A1 (ru) Вакцины против вируса гриппа и их применение
MX2012009581A (es) Vacunas para su uso en la profilaxis y tratamiento de la enfermedad del virus de influenza.
MX2015013235A (es) Vacuna peptidica para prevencion e inmunoterapia de la demencia tipo alzheimer.
UY37456A (es) Inmunoglobulinas y sus usos
AR102547A1 (es) Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
MY189495A (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
CU20180035A7 (es) Vectores atenuados de influenza para la prevención y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncológicas
AR093341A1 (es) Antigenos vacunales quimericos contra el virus de la hepatitis c
BR112017008952A2 (pt) métodos e composições para vírus recombinantes da dengue para desenvolvimento de vacina e diagnóstico
EA201792512A1 (ru) Составы для доставки антигенов респираторного синтициального вируса и норовируса в тонкий кишечник
MX363149B (es) Vacunas de nucleoproteina de la influenza.
IN2014DN09445A (es)
MX2019007924A (es) Vacunas contra la influenza.
WO2014152271A8 (en) Viral proteins as immunomodulatory agents and vaccine components
ECSP18039827A (es) Anticuerpo que neutraliza el virus respiratorio sincitial humano
AR110106A1 (es) Inmunoglobulinas y usos de estas
PT3584252T (pt) Antígenos, vetores, composições para o vírus da imunodeficiência humana e métodos da sua utilização
AR096455A1 (es) Vacuna para la malaria

Legal Events

Date Code Title Description
FG Grant of patent